NorthRock Partners’s Biogen BIIB Stock Holding History

NorthRock Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$329K	Sell	1,456 -11	-0.7%	-$2.33K	﹤0.01%	522
2026 Q2	$317K	Buy	1,467 +15	+1%	+$2.87K	﹤0.01%	520
2026 Q1	$266K	Sell	1,452 -17	-1%	-$3.13K	﹤0.01%	557
2025 Q4	$259K	Sell	1,469 -2,127	-59%	-$347K	﹤0.01%	507
2025 Q3	$504K	Buy	3,596 +480	+15%	+$64.9K	0.01%	530
2025 Q2	$391K	Buy	+3,116	New	+$388K	0.01%	464
2024 Q4	–	Sell	-1,406	Closed	-$273K	–	790
2024 Q3	$273K	Sell	1,406 -189	-12%	-$39.5K	0.01%	528
2024 Q2	$370K	Buy	1,595 +560	+54%	+$122K	0.01%	419
2024 Q1	$223K	Sell	1,035 -15	-1%	-$3.51K	0.01%	558
2023 Q4	$272K	Buy	+1,050	New	+$258K	0.01%	476

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

NorthRock Partners's BIIB Position: Q3 2026 in Review

NorthRock Partners reduced its Biogen (BIIB) stake by 0.75% in Q3 2026, selling an estimated $2.33K and leaving 1,456 shares worth $329K. The position accounts for ﹤0.01% of the portfolio, ranked #522.

NorthRock Partners first reported a position in BIIB in Q4 2023 and has held it in 10 quarters since. The position peaked at $504K in Q3 2025. 881 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

NorthRock Partners held 1,456 shares of Biogen worth $329K as of Q3 2026.
NorthRock Partners sold 11 Biogen shares in Q3 2026, an estimated $2.33K.
Biogen made up ﹤0.01% of NorthRock Partners's portfolio in Q3 2026, its #522 holding.
NorthRock Partners first reported a position in Biogen in Q4 2023 and has held it in 10 quarters since.
NorthRock Partners's Biogen position peaked at $504K in Q3 2025.
881 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on NorthRock Partners's 13F filing for Q3 2026, filed 13 Nov 2026.